

CANCER DISCOVERY CONTENTS

DECEMBER 2011 ■ VOLUME 1 ■ NUMBER 7

IN THIS ISSUE Highlighted research articlesvi

NEWS IN BRIEF Important news stories affecting the community.....541

NEWS IN DEPTH Q&A: William Sellers on Success in Small Molecules..... 543

Upcoming Battles in the War on Cancer..... 544

RESEARCH WATCH Selected highlights of recent articles of exceptional significance from the cancer literature.....547

ONLINE For more News and Research Watch, visit *Cancer Discovery* online at www.AACR.org/CDnews.

IEWS In The Spotlight

Anti-MET Targeted Therapy Has Come of Age: The First Durable Complete Response with MetMab in Metastatic Gastric Cancer.....550

Y. Feng and P.C. Ma

Commentary on Catenacci et al., p. 573

Genomic Investigation of Dedifferentiated Liposarcoma Suggests a Role for Therapeutic Targeting of the Tumor Epigenome.....555

P.S. Meltzer and L.J. Helman

Commentary on Taylor et al., p. 587

A Combined Epigenetic Therapy Equals the Efficacy of Conventional Chemotherapy in Refractory Advanced Non-Small Cell Lung Cancer.....557

M. Rodríguez-Paredes and M. Esteller

Commentary on Juergens et al., p. 598

CRKL as a Lung Cancer Oncogene and Mediator of Acquired Resistance to EGFR Inhibitors: Is It All That Is Cracked Up to Be? 560

M. Ladanyi

Commentary on Cheung et al., p. 608

REVIEW PI3K δ Inhibitors in Cancer: Rationale and Serendipity Merge in the Clinic..... 562

D.A. Fruman and C. Rommel

RESEARCH BRIEFS Durable Complete Response of Metastatic Gastric Cancer with Anti-Met Therapy Followed by Resistance at Recurrence..... 573





D.V. T. Catenacci, L. Henderson, S-Y. Xiao, P. Patel, R.L. Yauch, P. Hegde, J. Zha, A. Pandita, A. Peterson, and R. Salgia


Précis: An anti-MET monoclonal antibody elicited a 2-year complete response in a patient with metastatic gastric cancer with *MET* gene polysomy and autocrine HGF production.

A Novel Platform for Detection of CK⁺ and CK⁻ CTCs 580

C.V. Pecot, F.Z. Bischoff, J.A. Mayer, K.L. Wong, T. Pham, J. Bottsford-Miller, R.L. Stone, Y.G. Lin, P. Jaladurgam, J.W. Roh, B.W. Goodman, W.M. Merritt, T.J. Pircher, S.D. Mikolajczyk, A.M. Nick, J. Celestino, C. Eng, L.M. Ellis, M.T. Deavers, and A.K. Sood

Précis: An expanded antibody cocktail combined with a microfluidics platform directly incorporating FISH identifies nonepithelial CTCs.





Frequent Alterations and Epigenetic Silencing of Differentiation Pathway Genes in Structurally Rearranged Liposarcomas 587

B.S. Taylor, P.L. DeCarolis, C.V. Angeles, F. Brenet, N. Schultz, C.R. Antonescu, J.M. Scandura, C. Sander, A.J. Viale, N.D. Socci, and S. Singer

Précis: Dedifferentiated liposarcomas harbor recurring *HDAC1* mutations and exhibit aberrant methylomes, suggesting that epigenetic therapies may be effective in these tumors.

Amplification of *CRKL* Induces Transformation and Epidermal Growth Factor Receptor Inhibitor Resistance in Human Non-Small Cell Lung Cancers . . . 608

H.W. Cheung, J. Du, J.S. Boehm, F. He, B.A. Weir, X. Wang, M. Butaney, L.V. Sequist, B. Luo, J.A. Engelman, D.E. Root, M. Meyerson, T.R. Golub, P.A. Jänne, and W.C. Hahn

Précis: Overexpression of the *CRKL* adaptor protein activates oncogenic signaling pathways and promotes drug resistance in NSCLC.

RESEARCH ARTICLES

Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non-Small Cell Lung Cancer 598



R.A. Juergens, J. Wrangle, F.P. Vendetti, S.C. Murphy, M. Zhao, B. Coleman, R. Sebree, K. Rodgers, C.M. Hooker, N. Franco, B. Lee, S. Tsai, I.E. Delgado, M. A. Rudek, S.A. Belinsky, J.G. Herman, S.B. Baylin, M.V. Brock, and C.M. Rudin

Précis: Objective, long-lasting responses are observed in patients with NSCLC treated with azacitidine and entinostat.

Corrections

Correction: Ovarian Cancer Spheroids Use Myosin-Generated Force to Clear the Mesothelium 626

Correction: Forty Years of Translational Cancer Research 627

Correction: Drugs, Diagnostic Tests Approved Quickly 627

Acknowledgment to Reviewers 628

For more News and Research Watch, visit *Cancer Discovery* online at www.AACR.org/CDnews. Online-only News stories include the following:

- HDAC Inhibitors Show Benefits in Breast Cancer
- Phenotypic Profiling Identifies Novel Anticancer Drugs
- Automated Pathology Gives Accurate Predictions
- Triple-Acting Drug Boosts Prostate Cancer Survival
- Analyzing Intact Proteins with Mass Spectrometry
- FDA Pulls Approval for Avastin in Breast Cancer

ON THE COVER

Juergens and colleagues present results from a phase I/II trial showing that combined epigenetic therapy with azacitidine and entinostat can elicit objective responses, including one complete and one partial response, in refractory metastatic non-small cell lung cancer (NSCLC). A decreased methylation signature in response to treatment was associated with longer overall and progression-free survival, indicative of on-target epigenetic effects. Furthermore, several patients had objective responses to subsequent anticancer therapies. This combination epigenetic therapy may therefore be effective in reversing the epigenetic mechanisms driving the progression and resistance of NSCLC. For details, please see the article by Juergens and colleagues on page 598.



CANCER DISCOVERY

1 (7)

Cancer Discovery 2011;1:OF1-628.

Updated version Access the most recent version of this article at:
<http://cancerdiscovery.aacrjournals.org/content/1/7>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://cancerdiscovery.aacrjournals.org/content/1/7>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.